Aditxt Signs a Definitive Agreement to Acquire Appili Therapeutics Inc., Developer of a Biodefense Vaccine Funded by the U.S. Department of Defense (DoD)

Assets include the FDA-approved LIKMEZ™, the ATI-1701 tularemia vaccine defense program that has been awarded a USD $14 million non-dilutive award from the DoD, and the ATI-1801 topical...

Related Keywords

United States ,Canada ,Canadian ,Don Cilla ,Amro Albanna ,Francisella Tularensis ,Aditxt Inc ,Nelson Mullins Riley Scarborough ,Dentons Canada ,Saptalis Pharmaceuticals ,Richter Hampton ,Appili Therapeutics Inc ,Aird Berlis ,Adivir Inc ,World Health Organization ,Appili Special Committee ,Bloom Burton Co ,Us National Institutes Of Health ,Appili Therapeutics ,Arrangement Agreement ,Canada Business Corporations Act ,Approved Taste Masked Oral Suspension ,Live Attenuated Vaccine ,Investigational New Drug ,Priority Review Voucher ,Medical Countermeasures ,Topical Formulation ,Cutaneous Leishmaniasis ,Neglected Tropical Disease ,Canada Business Corporations ,Appili Shares ,Appili Shareholder ,Appili Share ,Share Consideration ,Appili Shareholders ,Aditxt Shares ,Transaction Aditxt ,United States Securities Act ,Nelson Mullins Riley ,Bloom Burton ,Appili Board ,Appili Special ,Promising Innovations Possible Together ,Nasdaq Stock Market ,Annual Report ,Quarterly Report ,Markets ,